Evotec SE
OTC:EVOTF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.05
8.58
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DE |
E
|
Evotec SE
XETRA:EVT
|
1.1B EUR |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.2T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
223.2B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
154.9B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.4T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.3B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.3B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.9B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.2B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.6B EUR |
Loading...
|
Market Distribution
| Min | -222 027.4% |
| 30th Percentile | -2% |
| Median | 2.2% |
| 70th Percentile | 6% |
| Max | 85 055.6% |
Other Profitability Ratios
Evotec SE
Glance View
Nestled within Germany's innovation-focused sector, Evotec SE has carved a niche for itself as a leading player in the field of drug discovery and development solutions. From its inception, Evotec has thrived on its commitment to delivering comprehensive solutions that expedite the journey from conceptualization to clinical success. At the core of its business model is a robust and scalable platform approach, which integrates cutting-edge technologies such as high-throughput screening, phenotypic screening, and computational biology. By leveraging these advanced methodologies, Evotec collaborates with pharmaceutical giants, biotech firms, and academic institutions, offering them customized services and shared-risk alliances. This symbiotic partnership model not only accelerates drug discovery but also minimizes the resource constraints typically associated with early-stage research. Evotec's revenue generation is intricately tied to its partnerships and collaborations, which involve milestone and royalty payments, alongside direct service fees. Its business strategy is propelled by a unique combination of proprietary drug development initiatives and strategic collaborative ventures. This dual-pronged approach allows Evotec to share the financial risk of drug development while maintaining potential upside through successful compounds. Moreover, the company's proactive investments in its own pipeline complement the service-based revenue, as they position Evotec to capture significant gains from future licensing or the eventual commercialization of internally researched drugs. With a strong emphasis on scientific excellence and commercial viability, Evotec meticulously balances innovation with strategic foresight, crafting a sustainable business that stands resilient amid the ever-evolving pharmaceutical landscape.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Evotec SE is -21%, which is below its 3-year median of -18.4%.
Over the last 3 years, Evotec SE’s Net Margin has increased from -25.8% to -21%. During this period, it reached a low of -26.3% on Mar 31, 2025 and a high of -10.7% on Dec 31, 2023.